The Case for Laboratory Developed Procedures: Quality and Positive Impact on Patient Care

Academic Pathology

Volumn 4, Issue , 2017, Pages

  Kaul, Karen L ^a   Sabatini, Linda M ^a   Tsongalis, Gregory J ^b   Caliendo, Angela M ^c   Olsen, Randall J ^d   Ashwood, Edward R ^e   Bale, Sherri ^f   Benirschke, Robert ^a   Carlow, Dean ^g   Funke, Birgit H ^h   Grody, Wayne W ⁱ   Hayden, Randall T ^j   Hegde, Madhuri ^k   Lyon, Elaine ^l   Murata, Kazunori ^g   Pessin, Melissa ^g   Press, Richard D ^m   Thomson, Richard B ^a  

^a NORTHSHORE UNIVERSITY HEALTHSYSTEM   (United States)

^b DARTMOUTH HITCHCOCK MEDICAL CENTER   (United States)

^c BROWN UNIVERSITY   (United States)

^d HOUSTON METHODIST HOSPITAL   (United States)

^e UNIVERSITY OF COLORADO SCHOOL OF MEDICINE   (United States)

^f GENEDX   (United States)

^g MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^h MASSACHUSETTS GENERAL HOSPITAL   (United States)

ⁱ UNIVERSITY OF CALIFORNIA   (United States)

^j ST JUDE CHILDREN S RESEARCH HOSPITAL   (United States)

^k EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^l ARUP LABORATORIES   (United States)

^m OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

more..

Author keywords

Clinical Laboratory Improvement Amendments; Food and Drug Administration; genomics; lab developed procedures; lab developed tests; molecular diagnostics; next generation sequencing

Indexed keywords

EID: 85038223824     PISSN: None     EISSN: 23742895     Source Type: Journal    
DOI: 10.1177/2374289517708309     Document Type: Article

References (176)

1. Hallworth MJ. The ‘70% claim’: what is the evidence base? Ann Clin Biochem. 2011;48:487–488.
2. Badrich T. Evidence-based laboratory medicine. Clin Biochem Rev. 2013;34:43–46.
3. US Food and Drug Administration. The public health evidence for FDA oversight of laboratory developed tests: 20 case studies. 2015. https://www.fda.gov/downloads/AboutFDA/ReportsManualsForms/Reports/UCM472777.pdf. Accessed April 27, 2017.
4. Association for Molecular Pathology. Facts FDA ignored: An analysis of the FDA report, “The public health evidence for FDA oversight of laboratory developed tests: 20 case studies”. 2015. https://amp.org/emailads/documents/AMPResponseFDACaseReportFinal.pdf. Accessed April 27, 2017.
5. Association for Molecular Pathology. Proposal for modernization of CLIA regulations for laboratory developed testing procedures (LDPs). 2015. http://www.amp.org/advocacy/documents/AMPCLIAmodernizationproposalFINAL8.14.15.pdf. Accessed April 27, 2017.
6. Whitley RJ. Viral encephalitis. N Engl J Med. 1990;323:242.
7. Whitley RJ, Lakeman F. Herpes simplex virus infections of the central nervous system: therapeutic and diagnostic considerations. Clin Infect Dis. 1995;20:414.
8. Lakeman FD, Whitley RJ. Diagnosis of herpes simplex encephalitis: application of polymerase chain reaction to cerebrospinal fluid from brain-biopsied patients and correlation with disease. National Institute of Allergy and Infectious Diseases Collaborative Antiviral Study Group. J Infect Dis. 1995;171:857.
9. Aurelius E, Johansson B, Sköldenberg B, Staland A, Forsgren M. Rapid diagnosis of herpes simplex encephalitis by nested polymerase chain reaction assay of cerebrospinal fluid. Lancet. 1991;337(8735):189.
10. CAP Microbiology Resource Committee. ID1 Participate Summary Report. Survey ID1-B 2015. Northfield, IL: College of American Pathologists; 2015.
11. Hirsch HH, Randhawa P, ; AST Infectious Diseases Community of Practice. BK polyomavirus in solid organ transplantation. Am J Transplant. 2013;13:179–188.
12. Drachenberg CB, Hirsch HH, Papadimitriou JC. Polyomavirus BK versus JC replication and nephropathy in renal transplant recipients: a prospective evaluation. Transplantation. 2007;84:323–330.
13. Hirsch HH, Knowles W, Dickenmann M. Prospective study of polyomavirus type BK replication and nephropathy in renal-transplant recipients. N Engl J Med. 2002;347:488–496.
14. Boeckh M, Ljungman P. How we treat cytomegalovirus in hematopoietic cell transplant recipients. Blood. 2009;113:5711–5719.
15. Ljungman P. Molecular monitoring of viral infections after hematopoietic stem cell transplantation. Int J Hematol. 2010,91:596–601.
16. Hibberd PL, Tolkoff-Rubin NE, Conti D. Preemptive ganciclovir therapy to prevent cytomegalovirus disease in cytomegalovirus antibody-positive renal transplant recipients. A randomized controlled trial. Ann Intern Med. 1995,123:18–26.
17. Wolf DG, Spector SA. Early diagnosis of human cytomegalovirus disease in transplant recipients by DNA amplification in plasma. Transplantation. 1993,56:330–334.
18. Razonable RR, Hayden RT. Clinical utility of viral load in management of cytomegalovirus infection after solid organ transplantation. Clin Microbiol Rev. 2013;26:703–727.
19. Kraft CS, Armstrong WS, Caliendo AM. Interpreting quantitative cytomegalovirus DNA testing: understanding the laboratory perspective. Clin Infect Dis. 2012;54:1793–1797.
20. Ljungman P, Hakki M, Boeckh M. Cytomegalovirus in hematopoietic stem cell transplant recipients. Hematol Oncol Clin North Am. 2011;25:151–169.
21. Atkinson C, Emery VC. Cytomegalovirus quantification: where to next in optimising patient management? J Clin Virol. 2011,51:223–228.
22. Fryer JF, Heath AB, Anderson R, Minor PD, ; Collaborative Study Group. Collaborative Study to Evaluate the Proposed 1st WHO International Standard for Human Cytomegalovirus (HCMV) for Nucleic Acid Amplification (NAT)-Based Assays. Geneva, Switzerland: World Health Organization; 2010. WHO ECBS Report 2010; WHO/BS/2010.2138.
23. de Sanjose S, Quint WG, Alemany L, ; Retrospective International Survey and HPV Time Trends Study Group. Human papillomavirus genotype attribution in invasive cervical cancer: a retrospective cross-sectional worldwide study. Lancet Oncol. 2010;11:1048–1056.
24. International Human Papillomavirus Reference Center. Human Papillomavirus Reference Clones [Internet]. Stockholm, SE: International Human Papillomavirus Reference Center; c2016. Accessed October 31, 2016.
25. de Villiers EM, Fauquet C, Broker TR, Bernard HU, zur Hausen H. Classification of papillomaviruses. Virology. 2004;324:17–27.
26. Gen-Probe. APTIMA® HPV 16 18/45 genotype assay. 2012. https://www.accessdata.fda.gov/cdrh_docs/pdf12/P120007c.pdf. Accessed May 5, 2017.
27. https://www.fda.gov/downloads/AdvisoryCommittees/CommitteesMeetingMaterials/MedicalDevices/MedicalDevicesAdvisoryCommittee/MicrobiologyDevicesPanel/UCM389491.pdf. Accessed May 5, 2017.
28. Third Wave Technologies. Cervista™ HPV 16/18: An in vitro diagnostic test for the detection of DNA from Human Papillomavirus (HPV) Type 16 and Type 18 in cervical specimens. 2008. https://www.accessdata.fda.gov/cdrh_docs/pdf8/P080015c.pdf. Accessed May 5, 2017.
29. Digene Corporation. Digene high-risk HPV DNA test HYBRID CAPTURE® 2. https://www.accessdata.fda.gov/cdrh_docs/pdf8/P080015c.pdf. Accessed May 5, 2017.
30. Wright TC, JrStoler MH, Sharma A, Zhang G, Behrens C, Wright TL, ; ATHENA (Addressing THE Need for Advanced HPV Diagnostics) Study Group. Evaluation of HPV-16 and HPV-18 genotyping for the triage of women with high-risk HPV+ cytology-negative results. Am J Clin Pathol. 2011;136:578–586.
31. Castellsague X, Alemany L, Quer M, ; ICO International HPV in Head and Neck Cancer Study Group. HPV involvement in head and neck cancers: comprehensive assessment of biomarkers in 3680 patients. J Natl Cancer Inst. 2016;108:djv403.
32. Ang KK, Harris J, Wheeler R. Human papillomavirus and survival of patients with oropharyngeal cancer. N Engl J Med. 2010;363:24–35.
33. Physician data query (PDQ(R)) update. J Natl Cancer Inst. 2012;104:176.
34. Pfister DG, Ang KK, Brizel DM, ; National Comprehensive Cancer Network. Head and neck cancers. J Natl Compr Canc Netw. 2011;9:596–650.
35. Fauci AS, Morens DM. Zika virus in the Americas—yet another arbovirus threat. N Engl J Med. 2016;374:601–604.
36. Morens DM, Fauci AS. Emerging infectious diseases: threats to human health and global stability. PLoS Pathog. 2013;9:e1003467.
37. Corman VM, Olschlager S, Wendtner CM, Drexler JF, Hess M, Drosten C. Performance and clinical validation of the RealStar MERS-CoV Kit for detection of Middle East respiratory syndrome coronavirus RNA. J Clin Virol. 2014;60:168–171.
38. Tang P, Louie M, Richardson SE, ; Ontario Laboratory Working Group for the Rapid Diagnosis of Emerging Infections. Interpretation of diagnostic laboratory tests for severe acute respiratory syndrome: the Toronto experience. CMAJ. 2004;170:47–54.
39. Burd E. Validation of laboratory developed molecular assays for infectious diseases. Clin Microbiol Rev, 2010;23:550–576.
40. Waggoner J, Pinsky B. Zika virus: diagnostics for an emerging pandemic threat. J Clin Microbiol. 2016;54:9–16.
41. Rasmussen SA, Jamieson DJ, Honein MA, Petersen LR. Zika virus and birth defects—reviewing the evidence for causality. N Engl J Med. 2016;374:1981–1987.
42. Nowak JA, Kaul KL. The role of community molecular diagnostics laboratories in the H1N1 pandemic. J Mol Diagn. 2009;11:369–370.
43. Landry ML, St George K. Laboratory diagnosis of Zika virus infection. Arch Path Lab Med. 2017;141:60–67.
44. Barenfanger J, Drake C, Leon N, Mueller T, Troutt T. Clinical and financial benefits of rapid detection of respiratory viruses: an outcomes study. J Clin Microbiol. 2000;38:2824–2828.
45. Wang HL, Lopategui J, Amin MB, Patterson SD. KRAS mutation testing in human cancers: the pathologists role in the era of personalized medicine. Adv Anat Pathol. 2010;17:23–32.
46. Lièvre A, Bachet JB, Le Corre D. KRAS mutation status is predictive of response to cetuximab therapy in colorectal cancer. Cancer Res. 2006;66:3992–3995. doi:10.1158/0008-5472.CAN-06-0191. PMID16618717.
47. Di Fiore F, Le Pessot F, Lamy A. KRAS mutation is highly predictive of cetuximab resistance in metastatic colorectal cancer. J Clin Oncol. 2007;25(18 suppl):10502. ASCO Annual Meeting Proceedings.
48. Whitehall V, Tran K, Umapathy A. A multicenter blinded study to evaluate KRAS mutation testing methodologies in the clinical setting. J Mol Diagn. 2009;11:543–552.
49. Weichart W, Schewe C, Lehmann A. KRAS genotyping of paraffin-embedded colorectal cancer tissue in routine diagnostics: comparison of methods and impact of histology. J Mol Diagn. 2010;12:35–42.
50. Kamel-Reid S, Zhang T, Persons DL, Nikiforova MN, Halling KC, ; Molecular Oncology Resource Committee of the College of American Pathologists. Validation of KRAS testing for anti-EGFR therapeutic decisions for patients with metastatic colorectal carcinoma. Arch Pathol Lab Med. 2012;136:26–32. doi: 10.5858/arpa.2011-0220-OA. http://www.ncbi.nlm.nih.gov/pubmed/22208484.
51. Allegra CJ, Jessup JM, Somerfield MR. American Society of Clinical Oncology Provisional Clinical Opinion: testing for KRAS mutations in patients with metastatic colorectal carcinoma to predict response to anti-epidermal growth factor receptor monoclonal antibody therapy. J Clin Oncol. 2009;27:2091–2095.
52. Practice guidelines established for KRAS mutation testing in colorectal cancers. National Comprehensive Cancer Network Guidelines on Colon and Rectal Cancers; 2008. http://www.nccn.org.
53. OncoGenetics.Org (July 2009). “FDA updates Vectibix and Erbitux labels with KRAS testing info”. 2014. OncoGenetics.Org. Accessed July 20, 2009.
54. Food and Drug Administration. Medical devices: Therascreen® KRAS RGQ PCR Kit—P110030. Accessed June 20, 2014.
55. Evaluation of Genomic Applications in Practice and Prevention (EGAPP) Working Group. Recommendations from the EGAPP Working Group: can testing of tumor tissue for mutations in EGFR pathway downstream effector genes in patients with metastatic colorectal cancer improve health outcomes by guiding decisions regarding anti-EGFR therapy? Genet Med. 2013;15:517–527. doi:10.1038/gim.2012.184.
56. Allegra CJ, Rumble RB, Hamilton SR, Roach N, Hantel A, Schilsky RL. Extended RAS gene mutation testing in metastatic colorectal carcinoma to predict response to anti-epidermal growth factor receptor monoclonal antibody therapy: ASCO provisional clinical opinion update 2015. J Clin Oncol. 2016;34:179–185. doi:10.1200/JCO.2015.63.9674.
57. CAP Molecular Oncology Committee. KRAS Participant Summary Report. Survey KRAS-B 2015. Northfield, IL: College of American Pathologists; 2015.
58. Riely GJ, Marks J, Pao W. KRAS mutations in non-small cell lung cancer. Proc Am Thorac Soc. 2009;6:201–205. doi:10.1512/pats200809-107LC.
59. Lovly C, Johnson D, Pao W, Sosman J. BRAF. My Cancer Genome. 2015. https://www.mycancergenome.org/content/disease/melanoma/braf/. Accessed April 27, 2017.
60. COSMIC, catalogue of somatic mutations in cancer. http://cancer.sanger.ac.uk/cosmic/gene/analysis?ln=BRAF. Accessed April 27, 2017.
61. GlaxoSmithKline. Tafinlar (darbrafenib) capsules label. 2014. http://www.accessdata.fda.gov/drugsatfda_docs/label/2014/202806s002lbl.pdf. Accessed April 27, 2017.
62. Mourah S, Denis MG, Narducci FE. Detection of BRAF V600 mutations in melanoma: evaluation of concordance between the Cobas® 4800 BRAF V600 mutation test and the methods used in French National Cancer Institute (INCa) platforms in a real-life setting. PLoS One. 2015;10: e0120232.
63. CAP Molecular Oncology Committee. BRAF Participant Summary Report. Survey BRAF-B 2015. Northfield, IL: College of American Pathologists; 2015.
64. Geiersbach KB, Samowitz WS. Microsatellite instability and colorectal cancer. Arch Pathol Lab Med. 2011;135:1269–1277.
65. Boland CR, Thibodeau SN, Hamilton SR. A National Cancer Institute workshop on microsatellite instability for cancer detection and familial predisposition: development of international criteria for the determination of microsatellite instability in colorectal cancer. Cancer Res. 1998;58:5248–5247.
66. Cicek MS, Lindor NM, Gallinger S. Quality assessment and correlation of microsatellite instability and immunohistochemical markers among population- and clinic-based colorectal tumors results from the Colon Cancer Family Registry. J Mol Diagn. 2011;13:271–281.
67. Popat S, Hubner R, Houlston RS. Systematic review of microsatellite instability and colorectal cancer prognosis. J Clin Oncol. 2005;23:609–618.
68. Sargent DJ, Marsoni S, Monges G. Defective mismatch repair as a predictive marker for lack of efficacy of fluorouracil-based adjuvant therapy in colon cancer. J Clin Oncol. 2010;28:3219–3226.
69. Sepulveda AR, Hamilton SR, Allegra CJ. Molecular biomarkers for the evaluation of colorectal cancer: guideline from the American Society for Clinical Pathology, College of American Pathologists, Association for Molecular Pathology, and American Society of Clinical Oncology. J Mol Diagn. 2017;19:187–225. doi:10.1016/j.jmoldx.2016.11.00.
70. Boyle TA, Bridge JA, Sabatini LM, ; College of American Pathologists Molecular Oncology Committee. Summary of microsatellite instability test results from laboratories participating in proficiency surveys: proficiency survey results from 2005 to 2012. Arch Pathol Lab Med. 2014;138:363–370.
71. Sharma SV, Bell DW, Settleman J, Haber DA. Epidermal growth factor receptor mutations in lung cancer. Nat Rev Cancer. 2007;7:169–181.
72. Siegelin MD, Borczuk AC. Epidermal growth factor receptor mutations in lung adenocarcinoma. Lab Invest. 2104;94:129–137.
73. Lindeman NI, Cagle PT, Beasley MB, ; College of American Pathologists International Association for the Study of Lung Cancer and Association for Molecular Pathology. Molecular testing guideline for selection of lung cancer patients for EGFR and ALK tyrosine kinase inhibitors. Guideline from the College of American Pathologists, International Association for the Study of Lung Cancer, and Association for Molecular Pathology. J Mol Diagn. 2013;15:415–453.
74. Pirker R, Periera JR, Szczesna A. Cetuximab plus chemotherapy in patient with advance non-small-cell lung cancer (FLEX): an open-label randomized phase III trial. Lancet. 2009;373:1525–1531.
75. Kris MG, Natale RB, Herbst RS. Efficacy of gefitinib, an inhibitor of the epidermal growth factor receptor tyrosine kinase, in symptomatic patients with non-small cell lung cancer: a randomized trial. JAMA. 2003;290:2149–2158.
76. Turner SA, Peterson JD, Pettus JR. The pitfalls of companion diagnostics: evaluation of discordant EGFR mutation results from a clinical laboratory and a central laboratory. J Mol Diagn. 2016;18:331–335.
77. CAP Molecular Oncology Committee. EGFR Participant Summary Report. Survey EGFR-B 2015. Northfield, IL: College of American Pathologists; 2015.
78. TM cancer hotspot panel for identification of clinically actionable somatic mutations. Clin Chem Lab Med. 2014;52:707–714.
79. Macintyre G, Ylstra B, Brenton JD. Sequencing structural variants in cancer for precision therapeutics. Trends Genet. 2016;32:530–542.
80. Ashley EA. Towards precision medicine. Nat Rev Genet. 2016;17:507–522.
81. Wheler JJ, Janku F, Naing A. Cancer therapy directed by comprehensive genomic profiling: a single center study. Cancer Res. 2016;76:3690–3701.
82. Schwaederle M, Daniels GA, Piccioni DE. On the road to precision cancer medicine: analysis of genomic biomarker actionability in 439 patients. Mol Cancer Ther. 2015;14:1730–1737.
83. Heuckmann JM, Thomas RK. A new generation of cancer genome diagnostics for routine clinical use: overcoming the roadblocks to personalized cancer medicine. Ann Oncol. 2015;26:1830–1837.
84. Goodwin S, McPherson JD, McCombie WR. Coming of age: ten years of next generation sequencing technologies. Nat Rev Genet. 2016;17:333–351.
85. Frampton GM, Fichtenholtz A, Otto GA. Development and validation of a clinical cancer genomic profiling test based on massively parallel DNA sequencing. Nat Botechnol. 2013;31:1023–1031.
86. De Abreu FB, Peterson JD, Amos CI, Wells WA, Tsongalis GJ. Effective quality management practices in routine clinical next generation sequencing. Clin Chem Lab Med. 2016;54:761–771.
87. Ananda G, Mockus S, Lundquist M. Development and validation of the JAX Cancer Treatment Profile™ for detection of clinically actionable mutations in solid tumors. Exp Mol Pathol. 2015;98:106–112.
88. CAP Molecular Oncology Committee. NGSST Participant Summary Report. Survey NGSST-A 2016. Northfield, IL: College of American Pathologists; 2016.
89. Hughes TP, Kaeda J, Branford S. Frequency of major molecular responses to imatinib or interferon alfa plus cytarabine in newly diagnosed chronic myeloid leukemia. N Engl J Med. 2003;349:1423–1432.
90. NCCN Clinical Practice Guidelines in Oncology. Chronic Myelogenous Leukemia. 2017. http://www.nccn.org. Accessed November 25, 2016.
91. Baccarani M., Deininger M., Rosti G.. European LeukemiaNet recommendations for the management of chronic myeloid leukemia. Blood. 2013;122: 872–884,.
92. Branford S, Fletcher L, Cross NC. Desirable performance characteristics for BCR-ABL measurement on an international reporting scale to allow consistent interpretation of individual patient response and comparison of response rates between clinical trials. Blood. 2008; 112:3330–3338.
93. White HE, Matejtschuk P, Rigsby P. Establishment of the first World Health Organization International Genetic Reference Panel for quantitation of BCR-ABL mRNA. Blood. 2010;116:e111–e117.
94. Cross NCP, White HE, Ernst T. Development and evaluation of a secondary reference panel for BCR-ABL1 quantification on the International Scale. Leukemia. 2016;30:1844–1852.
95. Brown JT, Laosinchai-Wolf W, Hedges JB. Establishment of a standardized multiplex assay with the analytical performance required for quantitative measurement of BCR-ABL1 on the international reporting scale. Blood Cancer J. 2011;1:e13.
96. CAP Molecular Oncology Committee. MRD Participant Summary Report. Survey MRD-A 2016. Northfield, IL: College of American Pathologists; 2016.
97. Sherman S, Pletcher BA, Driscoll DA. Fragile X syndrome: diagnostic and carrier testing. Genet Med. 2005;7:584–587.
98. Monaghan KG, Lyon E, Spector EB. ACMG standards and guidelines for fragile X testing: a revision to the disease-specific supplements to the Standards and Guidelines for Clinical Genetics Laboratories of the American College of Medical Genetics and Genomics. Genet Med. 2013:15:575–586.
99. Amos Wilson J, Pratt VM, Phansalkar A, ; Fragile Xperts Working Group of the Association for Molecular Pathology Clinical Practice Committee. Consensus characterization of 16 FMR1 reference materials: a consortium study. J Mol Diagn. 2008;10:2–12.
100. Hawkins M, Boyle J, Wright KE. Preparation and validation of the first WHO international genetic reference panel for Fragile X syndrome. Eur J Hum Genet. 2011;19:10–17.
101. Weck KE, Zehnbauer B, Datto M, Schrijver I, ; CAP/ACMG Biochemical and Molecular Genetics Resource Committee. Molecular genetic testing for fragile X syndrome: laboratory performance on the College of American Pathologists proficiency surveys (2001-2009). Genet Med. 2012;14:306–312.
102. Rubenstein WS. Inherited breast cancers. In: Leonard DBG. EDMolecular Pathology in Clinical Practice. New York, NY: Springer Science and Business Media; 2007.
103. Krock BL, Mao R, Best HD, Lyon E. Genomic applications in inherited genetic disorders. In: Netto GJ, Schriver I, eds. Genomic Applications in Pathology. New York, NY: Springer Science and Business Media; 2015. doi:10.1007/978-1-4939-072704_30.
104. Li MM, Datto M, Duncavage EJ. Standards and guidelines for the interpretation and reporting of sequence variants in cancer: a Joint Consensus Recommendation of the Association for Molecular Pathology, American Society of Clinical Oncology and the College of American Pathologists. J Mol Diagn. 2017;19:4–23. doi:10.1016/j.jmoldx.2016.10.002.
105. Richards S, Aziz N, Bale S, ; ACMG Laboratory Quality Assurance Committee. Standards and guidelines for the interpretation of sequence variants: a Joint Consensus recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology. Genet Med. 2017;17:405–424. doi:10.1038/gim.2015.30.
106. Kudalkar EM, Almontashiri NAM, Huang C. Multiplexes reference materials as controls for diagnostic next-generation sequencing: a pilot investigating applications for hypertrophic cardiomyopathy. J Mol Diag. 2016;18:882–889. doi:10.2016/j.jmoldx/2016/07/005.
107. Green RC, Berg JS, Grody WW, ; American College of Medical Genetics and Genomics. ACMG recommendations for reporting of incidental findings in clinical exome and genome sequencing. Genet Med. 2013;15:565–574. doi:10.1038/gim.2013.73. PMID: 23788249.
108. Duncavage EJ, Abel HJ, Pfeifer JD. In silico proficiency testing for clinical next-generation sequencing. J Mol Diagn. 2017;19:35–42. doi:10.1016/j.jmoldx.2016.09.005.
109. Teekakirikul P, Kelly MA, Rehm HL, Lakdawala NK, Funke BH. Inherited cardiomyopathies: molecular genetics and clinical genetic testing in the postgenomic era. J Mol Diagn. 2013;15:158–170. doi: 10.1016/j.jmoldx.2012.09.002.
110. Semsarian C, Ingles J, Maron MS, Maron BJ. New perspectives on the prevalence of hypertrophic cardiomyopathy. J Am Coll Cardiol. 2015;65:1249–1254. doi:10.1016/j.jacc.2015.01.019. Review. PMID: 25814232.
111. Alfares AA, Kelly MA, McDermott G. Results of clinical genetic testing of 2,912 probands with hypertrophic cardiomyopathy: expanded panels offer limited additional sensitivity. Genet Med. 2015;17:880–888. doi:10.1038/gim.2014.205. Erratum in: Genet Med. 2015;17:319. PMID: 25611685.
112. Pugh TJ, Kelly MA, Gowrisankar S. The landscape of genetic variation in dilated cardiomyopathy as surveyed by clinical DNA sequencing. Genet Med. 2014;16:601–608. doi:10.1038/gim.2013.204. PMID: 24503780.
113. Tiziano F, Palmieri V, Genuardi M, Zeppilli P. The role of genetic testing in the identification of young athletes with inherited primitive cardiac disorders at risk of exercise sudden death. Front Cardiovasc Med. 2016;3:28. doi:10.3389/fcvm.2016.00028. eCollection 2016.
114. Bagnall RD, Weintraub RG, Ingles J. A prospective study of sudden cardiac death among children and young adults. N Engl J Med. 2016;374:2441–2452. doi:10.1056/NEJMoa1510687. PMID: 27332903.
115. Parrini E, Conti V, Dobyns WB, Guerrini R. Genetic basis of brain malformations. Mol Syndromol. 2016;7:220–233.
116. Helbig I, Tayoun AA. Understanding genotypes and phenotypes in epileptic encephalopathies. Mol Syndromol. 2016;7:172–181.
117. Shmuely S, Sisodiya SM, Gunning WB, Sander JW, Thijs RD. Mortality in Dravet syndrome: a review. Epilepsy Behav. 2016;64:69–74. doi:10.1016/j.yebeh.2016.09.007.
118. Bhoj EJ, Li D, Harr M. Mutations in TBCK, encoding TBC1-domain-containing kinase, lead to a recognizable syndrome of intellectual disability and hypotonia. Am J Hum Genet. 2016;98:782–788.
119. Wicklund MP, Mendell JR. The limb girdle muscular dystrophies: our ever-expanding knowledge. J Clin Neuromuscul Dis. 2003;5:12–28.
120. Yonekawa T, Nishino I. Ullrich congenital muscular dystrophy: clinicopathological features, natural history and pathomechanism(s). J Neurol Neurosurg Psychiatry. 2015;86:280–287.
121. Broccolini A, Mirabella M. Hereditary inclusion-body myopathies. Biochim Biophys Acta. 2015;1852:644–650.
122. Falzarano MS, Scotton C, Passarelli C, Ferlini A. Duchenne muscular dystrophy: from diagnosis to therapy. Molecules. 2015;20:18168–18184.
123. Ankala A, da Silva C, Gualandi F. A comprehensive genomic approach for neuromuscular diseases gives a high diagnostic yield. Ann Neurol. 2015;77:206–214.
124. Ankala A, Hegde M. Genomic technologies and the new era of genomic medicine. J Mol Diagn. 2014;16:7–10.
125. Xue Y, Ankala A, Wilcox WR, Hegde MR. Solving the molecular diagnostic testing conundrum for Mendelian disorders in the era of next-generation sequencing: single-gene, gene panel, or exome/genome sequencing. Genet Med. 2015;17:444–451.
126. Nelson HD, Goddard K, Mitchell JP, Okinaka-Hu L, Pappas M, Zakner B. Risk Assessment, Genetic Counseling, and Genetic Testing for BRCA-Related Cancer: Systemic Review to Update the US Preventative Service Task Force Recommendation. Rockville (MD): Agency for Healthcare Research and Quality (US); 2013. Report No: 12-05164-EF-1.
127. NCCN Clinical Practice Guidelines in Oncology. Genetic/Familial High-Risk Assessment of Breast and Ovarian Cancer. 2017. http://www.nccn.org. Accessed December 7, 2016.
128. Metcalfe K, Gershman S, Ghadirian P. Contralateral mastectomy and survival after breast cancer in carriers of BRCA1 and BRCA2 mutations: retrospective analysis. BMJ. 2014;348: g226.
129. Domchek SM, Friebel TM, Singer CF. Association of risk-reducing surgery in BRCA1 or BRCA2 mutation carriers with cancer risk and mortality. JAMA. 2010;304:967–975.
130. Møller P, Seppälä T, Bernstein I, ; Mallorca Group (http://mallorca-group.eu). Cancer incidence and survival in Lynch syndrome patients receiving colonoscopic and gynaecological surveillance: first report from the prospective Lynch syndrome database. Gut. 2017;66:464–472. doi:10.1136/gutjnl-2015-309675.
131. Laimer M, Bauer J, Murrell DF., Epidemiology, Pathogenesis, Classification, and Clinical Features of Epidermolysis Bullosa. UpToDate; 2016. http://www.uptodate.com/contents/epidemiology-pathogenesis-classification-and-clinical-features-of-epidermolysis-bullosa. Accessed April 27, 2017.
132. GeneTests.org. https://www.genetests.org/search/tests.php?types%5B%5D=4626&methods%5B%5D=18&methods%5B%5D=3650&locations%5B%5D=USA&user_submitted=1&search=EPIDERMOLYSIS+BULLOSA&filter_status=1. Accessed November 4, 2016.
133. Fine JD. Inherited epidermolysis bullosa. Orphanet J Rare Dis. 2010;5:12.
134. Retterer K, Juusola J, Cho MT. Clinical application of whole-exome sequencing across clinical indications. Gene Med. 2016;18:696–704.
135. Yang Y, Muzny DM, Xia F. Molecular findings among patients referred for clinical whole-exome sequencing. JAMA. 2014;312:1870–1879.
136. Bordelon YM. Clinical neurogenetics: Huntington disease. Neurol Clin. 2013;31:1085–1094.
137. Huntington’s Disease Society of America. hdsa.org. Accessed December 26, 2016.
138. Wild EJ, Tabrizi SJ. Targets for future clinical trials in Huntington’s disease: what’s in the pipeline? Mov Disord. 2014;29:1434–1445.
139. Dix SP, Wingard JR, Mullins RE. Association of busulfan area under the curve with veno-occlusive disease following BMT. Bone Marrow Transplant. 1996;17:225–230. PubMed PMID: 8640171.
140. Slattery JT, Clift RA, Buckner CD. Marrow transplantation for chronic myeloid leukemia: the influence of plasma busulfan levels on the outcome of transplantation. Blood. 1997;89:3055–3060. PubMed PMID: 9108427.
141. Murphy CP, Harden EA, Thompson JM. Generalized seizures secondary to high-dose busulfan therapy. Ann Pharmacother. 1992;26:30–31. PubMed PMID: 1606341.
142. McDonald GB, Hinds MS, Fisher LD. Veno-occlusive disease of the liver and multiorgan failure after bone marrow transplantation: a cohort study of 355 patients. Ann Intern Med. 1993;118:255–267. PubMed PMID: 8420443.
143. Negrin RS., Treatment and Prevention of Hepatic Sinusoidal Obstruction Syndrome Following Hematopoietic Cell Transplantation. UpToDate: Wolters Kluwer. Accessed April 27, 2017.
144. Haire WD, Ruby EI, Gordon BG. Multiple organ dysfunction syndrome in bone marrow transplantation. JAMA. 1995;274:1289–1295. PubMed PMID: 7563534.
145. Rubenfeld GD, Crawford SW. Withdrawing life support from mechanically ventilated recipients of bone marrow transplants: a case for evidence-based guidelines. Ann Intern Med. 1996;125:625–633. PubMed PMID: 8849146.
146. McCune JS, Gibbs JP, Slattery JT. Plasma concentration monitoring of busulfan: does it improve clinical outcome? Clin Pharmacokinet. 2000;39:155–165. doi:10.2165/00003088-200039020-00005. PubMed PMID: 10976660.
147. 2016 Busulfan pharmacokinetic lab cross verification results. Seattle, WA: Seattle Cancer Care Alliance; 2016.
148. Palmer J, McCune JS, Perales MA. Personalizing busulfan-based conditioning: considerations from the American Society for Blood and Marrow Transplantation Practice Guidelines Committee. Biol Blood Marrow Transplant. 2016;22:1915–1925. doi:10.1016/j.bbmt.2016.07.013. PubMed PMID: 27481448.
149. Kushnir MM, Blamires T, Rockwood AL. Liquid chromatography-tandem mass spectrometry assay for androstenedione, dehydroepiandrosterone, and testosterone with pediatric and adult reference intervals. Clin Chem. 2010;56:1138–1147.
150. Herold D, Fitzgerald R. Immunoassays for testosterone in women: better than a guess? Clin Chem. 2003;49:1250–1251.
151. Demers L. Testosterone and estradiol assays: current and future trends. Steroids. 2008;73:1333–1338.
152. Vesper HW, Botelho JC, Wang Y. Challenges and improvements in testosterone and estradiol testing. Asian J Androl. 2014;16:178.
153. Singh RJ. Validation of a high throughput method for serum/plasma testosterone using liquid chromatography tandem mass spectrometry (LC-MS/MS). Steroids. 2008;73:1339–1344.
154. Kushnir M, Rockwood AL, Roberts WL. Performance characteristics of a novel tandem mass spectrometry assay for serum testosterone. Clin Chem. 2006;52:120–128.
155. Botelho JC, Shacklady C, Cooper HC. Isotope-dilution liquid chromatography-tandem mass spectrometry candidate reference method for total testosterone in human serum. Clin Chem. 2013;59:372–380.
156. Rosner W, Vesper H. Toward excellence in testosterone testing: a consensus statement. J Clin Endocrinol Metab. 2010;95:4542–4548.
157. Yun YM, Botelho JC, Chandler DW. Performance criteria for testosterone measurements based on biological variation in adult males: recommendations from the Partnership for the Accurate Testing of Hormones. Clin Chem. 2012;58:1703–1710.
158. Rosner W, Auchus RJ, Azziz R, Sluss PM, Raff H. Utility, limitations, and pitfalls in measuring testosterone: an endocrine society position statement. J Clin Endocrinol Metab. 2007;92:405–413.
159. The Center for Disease Control and Prevention Hormone Assay Standardization (HoST) Program. https://www.cdc.gov/labstandards/hs_standardization.html. Accessed November 16, 2016.
160. Mowry JB, Spyker DA, Brooks DE, McMillan N, Schauben JL. 2014 Annual Report of the American Association of Poison Control Centers’ National Poison Data System (NPDS): 32nd Annual Report. Clin Toxicol. 2015;53:962–1147.
161. Kraut JA, Kurtz I. Toxic alcohol ingestions: clinical features, diagnosis, and management. Clin J Am Soc Nephrol. 2008;3:208–225.
162. Brent J. Fomepizole for ethylene glycol and methanol poisoning. N Engl J Med. 2009;360:2216–2223.
163. Juenke JM, Hardy L, McMillin GA, Horowitz GL. Rapid and specific quantification of ethylene glycol levels: adaptation of a commercial enzymatic assay to automated chemistry analyzers. Am J Clin Pathol. 2011;136:318–324.
164. Porter WH, Rutter PW, Yao HH. Simultaneous determination of ethylene glycol and glycolic acid in serum by gas chromatography-mass spectrometry. J Anal Toxicol. 1999;23:591–597.
165. Shoemaker JD, Lynch RE, Hoffmann JW, Sly WS. Misidentification of propionic acid as ethylene glycol in a patient with methylmalonic acidemia. J Pediatr. 1992;120:417–421.
166. Netzel BC, Grebe SK, Carranza Leon BG. Thyroglobulin (Tg) testing revisited: Tg assays, TgAb assays, and correlation of results with clinical outcomes. J Clin Endocrinol Metab. 2015;100:E1074–E1083.
167. Hoofnagle AN, Wener M. inventors, University of Washington, assignee. Methods and compositions for detecting thyroglobulin in a biological sample. US patent 20,090,042,213. February 12, 2009.
168. Hoofnagle AN, Becker JP, Wener MH, Heinecke JW. Quantification of thyroglobulin, a low-abundance serum protein, by immunoaffinity peptide enrichment and tandem mass spectrometry. Clin Chem. 2008;54:1796–1804.
169. CLSI. Performance Standards for Antimicrobial Susceptibility Testing; Twenty-Seventh Informational Supplement. CLSI Document M100-S27. Wayne, PA: Clinical and Laboratory Standards Institute; 2017.
170. Humphries RM, Hindler JA. Emerging resistance, new antimicrobial agents…but no tests! the challenge of antimicrobial susceptibility testing in the current US regulatory landscape. Clin Infect Dis. 2016;63:83–88.
171. Bartsch SM, Huang SS, Wong KF. Impact of delays between Clinical and Laboratory Standards Institute and Food and Drug Administration revisions of interpretive criteria for carbapenem-resistant enterobacteriaceae. J Clin Microbiol. 2016;54:2757–2762.
172. Joseph L, Cankovic M, Caughron S. The spectrum of clinical utilities in molecular pathology testing procedures for inherited conditions and cancer. J Mol Pathol. 2016;18:605–619.
173. Lefterova MI, Suarez CJ, Banaei N, Pinsky BA. Next-generation sequencing for infectious disease diagnosis and management: a report of the Association for Molecular Pathology. J Mol Pathol. 2016;17:623–634.
174. Gong JZ, Cook JR, Greiner TC, ; Association for Molecular Pathology. Laboratory practice guidelines for detecting and reporting JAK2 and MPL mutations in myeloproliferative neoplasms. J Mol Pathol. 2013;15:733–744.
175. Cankovic M, Nikiforova MN, Snuderl M. The role of MGMT testing in clinical practice. J Mol Pathol. 2013;15:539–555.
176. Zehnbauer B, Lofton-Day C, Pfeifer J, Shaughnessy E, Goh L. Diagnostic quality assurance pilot: a model to demonstrate comparative laboratory test performance with an oncology companion device assay. J Mol Diagn. 2017;19:1–3. doi:10.1016/j.jmoldx.2016.10.001.